Izeltabart, CAS 2642078-60-0

Product Description: Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Juniper A Scribner, et al. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059.

CAS Number: 2642078-60-0

Molecular Weight: N/A

Compound Purity: 95.74

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: ADC Antibody

• Artikelnummer: MEXHY-P990027-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P990027-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK